At a glance
ClinicalIndex Comparison Record- ✓Confirmed chronic hepatitis C, genotype 1
- ✓Adult male or female
- ✓Treatment-naïve or treatment-experienced
- ✓Receiving paritaprevir/ritonavir/ombitasvir ± dasabuvir ± ribavirin per standard of care and local label
- ✕Participating in or intending to participate in a concurrent interventional therapeutic trial
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Colombia (outCome)
In Brief
An observational study for Chronic Hepatitis C. Completed, enrolled 66 participants across 6 sites.
Detailed Summary
This is a prospective, multi-center observational study in adult participants chronically infected with hepatitis C virus (HCV) receiving the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir with or without dasabuvir) with or without ribavirin (RBV). The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label. This study focused on collecting real world data. Follow-up visits, treatment, procedures and diagnostic methods followed physicians' routine clinical practice using a 12-week treatment regimen (four visits plus two interim data collection windows) or a 24-week treatment regimen (four visits plus three interim data collection windows) and is based on the anticipated regular follow-up for patients undergoing treatment for chronic hepatitis C (CHC). Participants are observed for the duration of the ABBVIE REGIMEN therapy and for up to 24 weeks after treatment completion.